Efficacy of Higher Positive End-Expiratory Pressure Ventilation Strategy in Patients With Acute Respiratory Distress Syndrome: A Systematic Review and Meta-Analysis

Ryoei Yamamoto 1, Sosuke Sugimura 2, Kazuki Kikuyama 3, Chihiro Takayama 4, Junichi Fujimoto 4, Koichi Yamashita 5, Yasuhiro Norisue 6, Chihiro Narita 7

1. Department of Healthcare Epidemiology, School of Public Health, Graduate School of Medicine, Kyoto University, Kyoto, JPN
2. Department of Medical Engineering, Faculty of Health Care Science, Himeji Dokkyo University, Hyogo, JPN
3. Department of Intensive Care Medicine, Showa University Hospital, Tokyo, JPN
4. Department of Intensive Care Medicine, Yokohama Rosai Hospital, Yokohama, JPN
5. Division of Critical Care Center, Kochi Red Cross Hospital, Kochi, JPN
6. Department of Emergency and Critical Care Medicine, Tokyo Bay Urayasu Ichikawa Medical Center, Urayasu, JPN
7. Department of Emergency Medicine, Shizuoka General Hospital, Aioi, JPN

Corresponding author: Chihiro Narita, chihiro_narita_co.jp@yahoo.co.jp

Abstract

Previous systematic reviews and meta-analyses assessing the pooled effects of higher positive end-expiratory pressure (PEEP) failed to show significantly reduced mortality in patients with acute respiratory distress syndrome (ARDS). Some new randomized controlled trials (RCTs) have been reported and an updated systematic review is needed to evaluate the use of higher PEEP in patients with ARDS.

We searched MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Igaku-Chuo-Zasshi, ICTRP, the National Institute of Health Clinical Trials Register, and the reference list of recent guidelines. We included RCTs to compare the higher PEEP ventilation strategy with the lower strategy in patients with ARDS. Two authors independently assessed the eligibility of the studies and extracted the data. The primary outcomes were 28-day mortality. The GRADE (Grading of Recommendations, Assessment, Development, and Evaluations) methodology was used to evaluate the certainty of the evidence.

Among the 6530 screened records, 16 randomized trials involving 4150 patients were included in our meta-analysis. When comparing higher PEEP versus lower PEEP, the pooled risk ratio (RR) for 28-day mortality was 0.85 (15 studies, n=4108, 95% CI 0.72 to 1.00, I²=58%, low certainty of evidence). Subgroup analysis by study participants with a low tidal volume (LTV) strategy showed an interaction (P for interaction, 0.001).

Our study showed that in patients with ARDS, the use of higher PEEP did not significantly reduce 28-day mortality compared to the use of lower PEEP.

Introduction And Background

Acute respiratory distress syndrome (ARDS) is a common clinical syndrome with substantial morbidity and mortality in the intensive care unit (ICU) [1]. Most patients with ARDS require mechanical ventilation and the mortality was 28–47.8% [2]. In the management of patients with ARDS, the application of positive end-expiratory pressure (PEEP) is one method to improve oxygenation in patients. PEEP prevents atelectasis, increases functional residual capacity, recruits alveoli, redistributes extravascular lung water, and improves ventilation-perfusion matching. The higher PEEP usually improves the PaO2/FiO2 ratio compared to a lower PEEP [3-7]. However, there is a potential risk of increasing dead space, carbon dioxide, and pressure injury.

The results of randomized controlled trials (RCTs) that evaluated the efficacy of higher PEEP were inconsistent [3,5,8-9]. The Cochrane Systematic Review of seven trials that involved 2,565 patients with ARDS showed that in-hospital mortality was not significantly reduced by higher PEEP [10]. Recent systematic reviews have demonstrated a trend toward a lower risk of mortality, but the difference was insignificant [6,11]. However, these studies did not include three RCTs published after 2018 [12-14].

Higher PEEP ventilation has potentially relevant benefits; however, the effects remain unclear. To update the Japanese ARDS guidelines 2016 [15], we conducted a systematic review and meta-analysis aimed to...
Review

Methods

Protocol and Registration

Our review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) protocol for RCTs. The protocol was submitted to the University Hospital Medical Information Network Clinical Trial Registry (UMIN-CTR) on July 12, 2020, before data extraction was initiated (identifier: UMIN000041074).

Eligibility Criteria

Randomized controlled trials (RCTs) or cluster RCTs were included. Crossover trials, quasi-randomized, and non-randomized trials were excluded. The target population included intubated patients with ARDS (age ≥16 years). ARDS was defined according to the Murray [16], American-European Consensus Conference (AECC) [17], and Berlin definition [18], or definitions determined by the authors in the study. We included studies that compared a higher PEEP ventilation strategy with the usual or lower PEEP ventilation strategy; a variety of PEEP settings were included. If there was a difference of more than 2 cmH2O in PEEP between the two groups during 24-72 hours after intervention due to differences in the methods of setting PEEP (FiO2/PEEP, targeted O2, research-defined protocols, programmatic algorithm, and PEEP titration by recruitment maneuver, compliance, and transpulmonary pressure), we included them in this review. Differences in the settings of the ventilation mode and target tidal volume were tolerated and incorporated. Because the effect of high-frequency oscillatory ventilation and airway pressure release ventilation were different from our scope, we excluded those studies that evaluated them.

Data Sources and Searches

We conducted a literature search of the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE through PubMed, EMBASE, Cumulative Index to Nursing and Allied Health Literature (CINAHL), and Igaku-Choo-Zasshi (ichi-shi) from inception until July 2020. Our search strategies are described in the appendices. We also searched for ongoing clinical trials in the following trial registries: The World Health Organization International Clinical Trials Registry Platform (http://apps.who.int/trialsearch/) and the United States National Institutes of Health Ongoing Trials Register ClinicalTrials.gov. We searched for reference lists of the guidelines on the management of ARDS and the extracted articles [6,15]. No language restrictions were applied to these searches.

Study Selection and Data Extraction

Titles and abstracts were independently evaluated for potential relevance by two reviewers (SS, JF, KY, KK, CT, and RY). Two reviewers independently assessed the full texts and study eligibility and verified the reasons for the exclusion of ineligible studies. Conflicts between two reviewers were resolved by discussion and where this failed, through arbitration by a third author (CN). Following the PRISMA statement, the selection process was recorded in a flow diagram with appropriate details. Data extraction was performed by two authors (SS, JF, KY, and RY) independently using standard data extraction sheets. Differences in opinions regarding data extraction were resolved using the same methods.

Type of Outcome Measures

The primary outcome was 28-day mortality. If a survival curve was available, we extracted the 28-day mortality. If 28-day mortality was not reported, we used the mortality of the nearest follow-up at 28 days. The secondary outcomes were longest follow-up mortality (longest follow-up regardless of the duration of follow-up employed), health-related quality of life (QOL), PaO2/FiO2 (P/F) ratio on day one, ventilation-free day (VFD) up to 28 days, hospital length of stay (LOS), and barotrauma (new pneumothorax, mediastinal emphysema, subcutaneous emphysema, new thoracic drainage, or author-defined barotrauma/ventilation-induced lung injuries (VILI)).

Assessment of Risk of Bias

Two reviewers independently assessed the risk of bias in the included studies using the Cochrane Collaboration tool for assessing the risk of bias in randomized trials [19]. These reviewers classified each potential risk of bias as “low,” “high,” or “unclear.” Disagreements between the reviewers regarding the risk of bias were resolved through discussion. If failed, a third reviewer (CN) resolved these disagreements.

Analysis and Results Synthesis
Measures of treatment effects were calculated using the Cochrane Review Manager software (version 5.3; Cochrane Collaboration, London, UK) for data synthesis and analysis. Dichotomous data (mortality, barotrauma) were expressed as RR with 95% CIs, and continuous data (QOL, VFD, LOS) were presented as mean difference (MD) with 95% CI.

The random-effects model was used for meta-analysis. The \( \chi^2 \) test and the \( I^2 \) statistic were used to measure heterogeneity. We considered that a P-value of less than 0.1 and greater than 60% in the \( \chi^2 \) and \( I^2 \) statistic tests, respectively, were significantly heterogeneous. To evaluate publication bias, funnel plots and Egger’s tests were performed, where each comparison included more than ten studies. Egger’s test was considered statistically significant at P< 0.05.

**Subgroup Analysis and Sensitivity Analysis**

We pre-planned the following subgroup analyses for primary outcomes (28-day mortality): the Berlin definition or not, LTV strategy (LTV in the comparison group or not), and P/F ratio ≤200 mmHg at the time of inclusion. We performed sensitivity analyses that included only studies with a low risk of bias to evaluate the robustness of our inferences for the primary outcomes.

**Assessment of the Certainty of the Evidence**

To evaluate the quality of the evidence, the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) considerations were used classifying the quality as “high,” “moderate,” “low,” or “very low.” We used the methods and recommendations described in the Cochrane Handbook for Systematic Reviews of Intervention [20].

**Results**

**Study Selection**

After screening 6530 references, 114 records were evaluated in detail and 97 were excluded (Figure 1). Seventeen RCTs met the inclusion criteria [3-5,8-9,12-14,21-28], and one trial assessed the effects of higher PEEP during extracorporeal membrane oxygenation (ECMO) [29]. Therefore, 16 randomized trials involving 4150 patients were included in the quantitative synthesis to compare higher PEEP versus lower PEEP.
One record did not describe post-intervention PEEP levels, and one record was of unclear design.

† Two records were interim analyses reports, one record was the first report of Amato 1998 [8].

PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses; CENTRAL: Cochrane Central Register of Controlled Trials; CINAHL: Cumulative Index to Nursing and Allied Health Literature; ICTRP: International Clinical Trials Registry Platform; PEEP: positive end-expiratory pressure; ECMO: extracorporeal membrane oxygenation

Study Characteristics

The characteristics of this study are summarized in Table 1. ARDS was defined by the lung injury severity score (LISS) [8], AECC criteria [3,5,9,21-26], Berlin definition [12-14,27-29], and the author’s definition [4]. Most studies used the P/F ratio as an inclusion criterion. The intervention procedure varied across the studies. PEEP adjustments in the intervention groups were performed using the PEEP table in three of 16 studies [3-4,22], PEEP above the lower inflection point of the pressure-volume curve of the respiratory system (Pflex) in three of 16 studies [8-9,21], and compliance, including the decremental PEEP method, in four of 16 studies [13,24-26]. The mean level of PEEP on the first day in the high PEEP group ranged from 10.0 to 18.7 cm H₂O, and in the control group, it was 6.8-12.0 cm H₂O. The levels of PEEP on Days 1, 3, and 7 are described in Table 2.
| Study          | No. of center | Definition of ARDS | *Severity P/F ratio | Intervention | Control | Mortality Outcome |
|---------------|---------------|--------------------|---------------------|--------------|---------|-------------------|
| Amato 1998    | 2             | LISS               | NA                  | PEEP at Pflex plus 2 cm H₂O, Vt 6 ml/kg BW, PCV | PEEP set to O₂ goals (FiO₂ < 60 %), Vt 12 ml/kg BW, VCV | ICU, 28-day, In-hospital |
| Ranieri 1999  | 2             | AECC ≤200          | PEEP at Pflex plus 2 to 3 cm H₂O, Vt 5-8 ml/kg IBW, VCV | PEEP titrated by PEEP trial, Pplat<35cmH₂O, VCV | 28-day |
| Brower 2004   | 23            | AECC ≤300          | PEEP table (Higher PEEP group), Vt 6ml/kg PBW, VCV | PEEP table (Lower-PEEP group), Vt 6ml/kg PBW, VCV | 30-day (from figure), In-hospital |
| Long 2006     | 1             | AECC               | PEEP table, Vt 6ml/kg PBW, VCV | PEEP titrated static P-V curve, Vt<8 ml/kg IBW, VCV | 28-day |
| Study | Year | Definition | PEEP | Vt | Days | Endotracheal Tube |
|-------|------|------------|------|----|------|------------------|
| Villar 2006 | 8 | AECC | ≤200 | PEEP at Pflex plus 2 cm H₂O, Vt of 5-8 ml/kg PBW, PCV | ICUs, 30-day (from figure), In-hospital |
| Meade 2008 | 30 | Author's definition | ≤250 | PEEP table, Vt 4-8ml/kg PBW, PCV | ICU, 28-day, In-hospital |
| Mercat 2008 | 37 | AECC | ≤300 | PEEP titrated by airway pressure (<Pplat 28 to 30 cm H₂O), Vt 6ml/kg PBW, VCV | 28-day, In-hospital |
| Talmor 2008 | 1 | AECC | ≤300 | PEEP titrated by Ptp (0 to 10 cm H₂O), Vt 6±2 ml/kg PBW, VCV | 28-day |
| Hodgson 2011 | 1 | AECC <300 | PEEP at decremental PEEP plus 2.5cm H₂O, Vt6±6ml/kg PBW, PCV | ICU, 28-day, In-hospital |
| Kacmarek 2016 | 20 | AECC | ≤200 | PEEP at decremental PEEP plus 3cm H₂O, Vt 6ml/kg PBW, VCV | ICU, 28-day, In-hospital |
| Li 2017 | 2 | Berlin definition | ≤200 | PEEP set according to Ptp 10cmH₂O, Vt 6ml/kg, | 28-day |
| ART 2017 | 120 | AECC | ≤200 | PEEP at maximum alveolar recruitment by compliance plus 2 cmH₂O, Vt 4-6ml/kg PBW, Pplat ≤30cmH₂O, VCV | ICU, 28-day, In-hospital |
| Nguyen 2019 | 1 | Berlin definition | ≤200 | PEEP at the best compliance plus 2cmH₂O, Vt 6ml/kg, VCV | 28-day |
| Hodgson 2019 | 35 | Berlin definition | ≤200 | PEEP at the level of desaturation plus 2.5 cmH₂O, Vt 4-6ml/kg, PCV | ICU, 28-day, 90-day, In-hospital |
| Wang. B 2019 | 1 | Berlin definition | NA | PEEP titrated by esophageal pressure (5 to 8 cm H₂O), Vt 6-8 ml/kg IBW, VCV | NA |
| Salem 2020 | 1 | Berlin definition | NA | PEEP titrated by LUS aeration score, Vt 4-8ml/kg PBW, VCV | 28-day |
| Higher PEEP vs Lower PEEP with ECMO | | | | | |
| Wang. R 2020 | 1 | Berlin definition | ≤80 | PEEP titrated by expiratory Ptp (0 and 5 cm H₂O), Ppeak less than 25 cm H₂O, P/CV | 30-day (from figure), 60-day |

**TABLE 2: Characteristics of selection studies**

ARDS: acute respiratory distress syndrome; AECC: American-European Consensus Conference; ICU: intensive care unit; P/F: PaO₂/FiO₂; PEEP: positive end-expiratory pressure; LISS: lung injury severity score; Pflex: lower inflection point of pressure-volume curve; Pplat: plateau pressure during an inspiratory pause; Ppeak: peak pressure; Ptp: transpulmonary pressure; Vt: tidal volume; BW: body weight; PBW: predicted body weight; VCV: volume-controlled ventilation; PCV: pressure-controlled ventilation; NA: no data

* Severity used in inclusion criteria

**Risk of Bias Assessment**

The risk of bias for mortality was "low" when comparing higher PEEP and lower PEEP (Figure 2). Blinding was not performed because of the nature of the intervention in all studies. Because unblinding does not influence objective outcomes, we evaluated mortality and P/F ratio as a low risk of bias. While subjective outcomes, such as QOL, VFD up to 28 days, hospital LOS, and barotrauma were assessed as "unclear" risk of bias related to blinding. For incomplete outcome data, one study was evaluated as "high" risk of bias due to the exclusion of seven patients after randomization [21]. For selective outcome reporting, studies for which protocols were not available or details could not be obtained at the trial registration site were rated as "unclear" risk of bias. In Brower, the protocol was changed during the trial, and the primary endpoint was switched from "28-day mortality" to "proportion of patients who died before discharge without respiratory
support" [3]. Therefore, we evaluated the risk of bias as "high;" no publication bias was detected (Figure 3).

| Study                | D1 | D2 | D3 | D4 | D5 | D6 | D7 | Overall |
|----------------------|----|----|----|----|----|----|----|---------|
| Amato 1998 [8]       | +  | +  | +  | +  | +  | -  | +  | +       |
| Ranieri 1990 [21]    | -  | +  | +  | +  | -  | +  | +  | X       |
| Brower 2004 [3]      | +  | +  | +  | +  | X  | +  | +  | X       |
| Long 2006 [22]       | +  | -  | +  | -  | -  | +  | -  | -       |
| Vilasar 2006 [9]     | +  | +  | +  | +  | -  | +  | +  | +       |
| Meade 2008 [4]       | +  | +  | +  | +  | +  | -  | +  | +       |
| Mercat 2008 [5]      | +  | +  | +  | +  | +  | +  | +  | +       |
| Talmor 2008 [23]     | -  | +  | +  | +  | +  | +  | +  | +       |
| Hodgson 2011 [24]    | +  | +  | +  | +  | +  | +  | +  | +       |
| Kacmarek 2016 [25]   | +  | +  | +  | +  | +  | +  | +  | +       |
| Li 2017 [27]         | +  | -  | +  | +  | +  | -  | +  | +       |
| ART 2017 [26]        | +  | +  | +  | +  | +  | +  | +  | +       |
| Nguyen 2019 [13]     | -  | -  | +  | +  | +  | -  | +  | -       |
| Hodgson 2019 [24]    | +  | +  | +  | +  | +  | +  | +  | +       |
| Wang, B 2019 [28]    | +  | -  | +  | +  | X  | X  | +  | X       |
| Salem 2020 [14]      | -  | +  | +  | +  | -  | +  | +  | +       |
| Wang, R 2020 [29]    | +  | +  | +  | +  | +  | +  | +  | +       |

D1: Random sequence generation
D2: Allocation concealment
D3: Blinding of participants and personnel
D4: Blinding of outcome assessment
D5: Incomplete outcome data
D6:Selective reporting
D7: Other sources of bias

FIGURE 2: Risk of bias summary
FIGURE 3: Funnel plot for mortality

SE (log [RR]): standard error (log [risk ratio]); RR: risk ratio
A: 28-day mortality; B: Longest follow-up mortality

Meta-Analyses of the Results

Regarding the primary outcome (28-day mortality), the pooled RR was 0.85 (15 studies, n=4108, 95% CI 0.72 to 1.00, I²=58%, Figure 4A). For the 4108 patients involved in the 15 studies and contributing to the longest follow-up mortality data, the pooled RR was 0.87 (15 studies, 95% CI 0.76 to 1.00, I²=55%; Figure 4B). None of the studies reported QOLs. Fourteen studies involved 3945 patients that reported a P/F ratio on day one; higher PEEP significantly increased the P/F ratio compared to lower PEEP (MD 48.9 mmHg, 95% CI 31.9 to 65.8, I²=97%, Figure 5A). There was no significant difference in VFD up to 28 days (11 studies, n=2988, MD 1.82 days, 95% CI -0.57 to 4.01, I²=76%, Figure 5B), hospital length of stay (6 studies, n=2392, MD 0.86 days, 95% CI -3.08 to 4.80, I²=77%, Figure 6A), or barotrauma (13 studies, n=3861 RR 1.02, 95% CI 0.67 to 1.57, I²=56%, Figure 6B).
FIGURE 4: Forest plot of the comparison of higher PEEP ventilation versus lower PEEP ventilation for mortality

PEEP: positive end-expiratory pressure; CI: confidence interval; M-H: Mantel-Haenszel method

(A) 28-day mortality. Data extracted from the Kaplan-Meier curve at 28 days; Brower 2004 [3], and Villar 2006 [9], in-hospital mortality; Hodgson 2011 [24], and 28-day mortality; other studies. (B) The longest follow-up mortality. Data extracted from the Kaplan-Meier curve at 28 days; Villar 2006 [9], 28-day mortality; Ranieri 1999 [21], Long 2006 [22], Li 2017 [27], Nguyen 2019 [13], and Salem 2020 [14], 60-day mortality; Brower 2004 [3], Mercat 2008 [5], and Kacmarek 2018 [25], six-month mortality; Talmor 2008 [23], ART 2017 [26], and Hodgson 2019 [24], and in-hospital mortality; other studies.

| Study or Subgroup | Higher PEEP Events | Lower PEEP Events | Total | Weight | Risk Ratio | M-H Random, 95% CI | Year |
|-------------------|--------------------|-------------------|-------|--------|------------|-------------------|------|
| Amato 1999 [3]    | 15 23              | 17 24             | 5.7%  | 0.03   | 0.03       | 0.03              | 1999 |
| Ranieri 1999 [21] | 7 18               | 11 19             | 4.1%  | 0.07   | 0.07       | 0.07              | 1999 |
| Brower 2004 [3]   | 85 276             | 61 273            | 10.2% | 1.05   | 1.05       | 1.05              | 2004 |
| Villar 2006 [9]   | 20 53              | 33 45             | 8.0%  | 0.55   | 0.55       | 0.55              | 2006 |
| Long 2006 [22]    | 8 14               | 5 16              | 2.9%  | 1.83   | 1.83       | 1.83              | 2006 |
| Mercat 2008 [5]   | 107 385            | 119 382           | 12.0% | 0.88   | 0.88       | 0.88              | 2008 |
| Moise 2008 [4]    | 135 475            | 164 508           | 13.3% | 0.86   | 0.86       | 0.86              | 2008 |
| Tamor 2006 [23]   | 5 30               | 12 21             | 2.6%  | 0.43   | 0.43       | 0.43              | 2008 |
| Hodgson 2011 [24] | 3 10               | 2 10              | 1.0%  | 1.50   | 1.50       | 1.50              | 2011 |
| Kacmarek 2018 [25]| 22 96              | 27 101            | 6.0%  | 0.83   | 0.83       | 0.83              | 2018 |
| Li 2017 [27]      | 14 43              | 6 21              | 3.2%  | 1.14   | 1.14       | 1.14              | 2017 |
| ART 2017 [26]     | 377 1031           | 361 909           | 16.6% | 1.12   | 1.12       | 1.12              | 2017 |
| Nguyen 2019 [13]  | 15 33              | 23 33             | 8.0%  | 0.78   | 0.78       | 0.78              | 2019 |
| Hodgson 2019 [24] | 14 57              | 15 56             | 6.7%  | 0.92   | 0.92       | 0.92              | 2019 |
| Saken 2020 [14]   | 2 33               | 9 36              | 1.2%  | 0.22   | 0.22       | 0.22              | 2020 |

Total events 706 755

Test for overall effect Z = 1.46 (P = 0.06)

| Study or Subgroup | Events | Total | Weight | Risk Ratio | M-H Random, 95% CI |
|-------------------|--------|-------|--------|------------|-------------------|
| Amato 1999 [3]    | 15 23  | 17 24 | 5.7%   | 0.03       | 0.03              |
| Ranieri 1999 [21] | 7 18   | 11 19 | 4.1%   | 0.07       | 0.07              |
| Brower 2004 [3]   | 85 276 | 61 273| 10.2%  | 1.05       | 1.05              |
| Villar 2006 [9]   | 20 53  | 33 45 | 8.0%   | 0.55       | 0.55              |
| Long 2006 [22]    | 8 14   | 5 16  | 2.9%   | 1.83       | 1.83              |
| Mercat 2008 [5]   | 107 385| 119 382| 12.0%  | 0.88       | 0.88              |
| Moise 2008 [4]    | 135 475| 164 508| 13.3%  | 0.86       | 0.86              |
| Tamor 2006 [23]   | 5 30   | 12 21 | 2.6%   | 0.43       | 0.43              |
| Hodgson 2011 [24]| 3 10   | 2 10  | 1.0%   | 1.50       | 1.50              |
| Kacmarek 2018 [25]| 22 96  | 27 101| 6.0%   | 0.83       | 0.83              |
| Li 2017 [27]      | 14 43  | 6 21  | 3.2%   | 1.14       | 1.14              |
| ART 2017 [26]     | 377 1031| 361 909| 16.6%  | 1.12       | 1.12              |
| Nguyen 2019 [13]  | 15 33  | 23 33 | 8.0%   | 0.78       | 0.78              |
| Hodgson 2019 [24]| 14 57  | 15 56 | 6.7%   | 0.92       | 0.92              |
| Saken 2020 [14]   | 2 33   | 9 36  | 1.2%   | 0.22       | 0.22              |

Total events 849 899

Test for overall effect Z = 1.80 (P = 0.06)
FIGURE 5: Forest plot of the comparison of higher PEEP ventilation versus lower PEEP ventilation for P/F ratio at day 1 and VFD up to 28 days.

CI, confidence interval; IV, inverse variance; PEEP, positive end-expiratory pressure.
(A): PaO₂/FiO₂ ratio on day 1; (B) Ventilator-free days up to 28 days.

FIGURE 6: Forest plot of the comparison of higher PEEP ventilation versus lower PEEP ventilation for the length of hospital stay and barotrauma.

PEEP: positive end-expiratory pressure; CI: confidence interval; IV: inverse variance; M–H: Mantel–Haenszel method.
(A) Length of hospital stay; (B) Barotrauma.

Subgroup and Sensitivity Analyses

Subgroup analyses of 15 studies reporting 28-day mortality [3-5,8-9,12-14,21-27] by study participants with a definition of ARDS (Berlin vs. other) and 12 studies reporting 28-day mortality [3-5,9,12,13,21,23-27] by 2022 Yamamoto et al. Cureus 14(7): e26957. DOI 10.7759/cureus.26957

10 of 17
study participants with the severity of inclusion criteria (P/F ratio≤200 vs. >200) did not show any subgroup interaction (Table 3). The subgroup analysis of 15 studies reporting 28-day mortality [3-5,8-9,12-13,21-27] by study participants with LTV strategy (LTV in the comparison group or not) demonstrated a significant interaction in mortality (test for subgroup differences: χ² = 10.33, P for interaction 0.001; Table 3).

| Subgroup                          | Studies | Patients | Pooled risk ratio | I² (%) | p-value |
|-----------------------------------|---------|----------|-------------------|--------|---------|
| Participants: definition         | 15      | 4108     |                   | 0      | 0.77    |
| Berlin definition                 | 4       | 303      | 0.81 [0.55, 1.18]  |        |         |
| Other definition                  | 11      | 3805     | 0.86 [0.72, 1.03]  |        |         |
| Participants: severity            | 12      | 3965     |                   | 0      | 0.38    |
| P/F ratio≤200                     | 8       | 1646     | 0.80 [0.61, 1.05]  |        |         |
| P/F ratio>200                     | 4       | 2319     | 0.92 [0.81, 1.04]  |        |         |
| Participants: LTV                 |         | 4108     |                   | 90.3   | 0.001   |
| LTV in both group                 | 12      | 3923     | 0.94 [0.82, 1.09]  |        |         |
| Without LTV in comparison         | 3       | 185      | 0.56 [0.42, 0.75]  |        |         |

TABLE 3: Subgroup analyses of 28-day mortality related to higher PEEP ventilation

PEEP: positive end-expiratory pressure; P/F: PaO₂/FiO₂ ratio; LTV: low tidal volume.

We performed a sensitivity analysis exploring the influence of a high risk of bias. Two of the 15 studies contributing to 28-day mortality were rated as having a high risk of bias. The pooled RR was similar to that of the primary analysis (13 studies, n=3522, RR 0.83, 95%CI 0.69 to 1.00, I²=63%). In a post-hoc meta-analysis, limited to studies conducted after 2000, we found that the pooled RR was 0.89 (13 studies, n=4018, 95%CI 0.75 to 1.04, I²=57%).

Certainty of Evidence

The certainty of evidence for mortality was downgraded by two levels for inconsistency (different direction of effect in studies and high heterogeneity) and imprecision (wide confidence interval) and was considered low. The details of the other outcomes are presented in Table 4.
TABLE 4: Summary of findings

PEEP: positive end-expiratory pressure; RCT: randomized control trial; ADL/QOL: activities of daily living/quality of life; P/F: PaO_2/FiO_2 ratio; CI: confidence interval; RR: risk ratio; MD: mean difference.

| Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Higher PEEP | Lower PEEP | Relative (95% CI) | Absolute (95% CI) |
|--------------|--------------|---------------|--------------|-------------|----------------------|--------------|------------|----------------|------------------|
| Mortality (nearest 28 days) | 15 | RCT | not serious | serious, a, b | not serious, serious, c | none | 759/2030 (36.5%) | 750/2038 (36.7%) | RR 0.85 (0.72 to 1.00) | 55 fewer per 1,000 (from 103 fewer to 0 fewer) |
| Mortality (Longest follow up) | 15 | RCT | not serious | serious, a, b | not serious, serious, c | none | 849/2030 (41.4%) | 868/2038 (43.7%) | RR 0.87 (0.76 to 1.00) | 52 fewer per 1,000 (from 105 fewer to 0 fewer) |
| ADL/QOL: not reported | - | - | - | - | - | - | - | - | - |
| P/F ratio at day 1 | 14 | RCT | not serious | serious, a, b | not serious | none | 1976 | 1969 | MD 48.87 mmHg higher (31.91 higher to 65.83 higher) |
| Ventilator free days at 28 | 11 | RCT | not serious | very serious, a, b | not serious, serious, c | none | 1483 | 1485 | MD 1.82 day higher (0.37 lower to 4.01 higher) |
| Length of hospital stay | 8 | RCT | not serious | very serious, a, b | not serious, serious, c | none | 1175 | 1217 | MD 0.86 days higher (3.08 lower to 4.8 higher) |
| Barotrauma | 10 | RCT | not serious | very serious, a, b | not serious, very serious, c, d | none | 152/1917 (7.9%) | 132/1964 (6.8%) | RR 1.02 (0.67 to 1.57) | 1 more per 1,000 (from 23 fewer to 39 more) |

Discussion

Summary of Key Findings

The current systematic review and meta-analysis showed that a higher PEEP ventilation strategy did not significantly reduce the 28-day and longest follow-up mortality of adult patients with ARDS. While the P/F ratio was increased in the higher PEEP group, there was no significant effect on VFD at 28 days and hospital LOS. The higher PEEP ventilation strategy did not appear to significantly increase the risk of barotrauma.

Relation With Previous Systematic Reviews

Previous systematic reviews of the effect of higher PEEP on patients with ARDS have not reported a significant mortality benefit with high PEEP [11,26]. Our systematic review included several recent RCTs [12-14,25-27], but the results remained unchanged. A sensitivity analysis that excluded studies with a high risk of bias showed similar results. However, these results should be carefully interpreted. This was because of the high heterogeneity in the included studies. In some RCTs, the control group had non-LTV ventilation, and the intervention group had open-lung strategy ventilation that combined higher PEEP with LTV. This heterogeneity may be important for interpreting the results. In our review, we conducted a subgroup analysis to examine whether there was an interaction between LTV and higher PEEP. This subgroup analysis suggested that there was an interaction when combined with LTV. Walkey et al. reported similar results to our analysis, which involved a recent RCT [6]. These results suggest that not only high PEEP but also a combination of LTV may be more effective. However, since the main effect was not significant in this study, the results of the subgroup analysis must be interpreted with caution.
We performed a subgroup analysis of the definition of ARDS and differences in severity at inclusion (P/F<200) and examined the interaction on the effect of higher PEEP, but found no interaction on mortality. A meta-analysis of individual patient data from three trials [3-5] by Briel et al. showed that patients with ARDS (P/F<200 mmHg) may benefit from higher PEEP than patients with mild ARDS [7]. There are several possible reasons for this difference in results; one reason is that we performed a subgroup analysis by P/F ratio at the inclusion criteria. To maintain the randomness of covariates between subgroups, it is necessary to perform subgroup analysis with or without the inclusion criteria of severity or stratified randomization by severity. Briel et al. adjusted for confounders to equalize the groups, but this may have been insufficient [7].

The second reason is the difference in the number of included studies. In our study, we included 12 RCTs in the subgroup analysis. Under the assumption that there was no bias, the pooled effect size would have been closer to the true value if the number of included studies increased. However, the sample size was insufficient for detecting small effects in the subgroups in our study. Until further evidence is accumulated, it is not clear whether higher PEEP should be applied depending on the severity of the target patients.

**Implications for Practice and Further Study**

Higher PEEP did not show a significant reduction in mortality, but it did show a consistent effect on improving oxygenation [10-11,26]. A higher PEEP usually improves the PaO₂/FiO₂ compared to a lower PEEP. PEEP prevents atelectasis, increases functional residual capacity, and improves ventilation-perfusion matching. Our study also showed that oxygenation could be improved without increasing pressure injury. In the intervention groups of most of the included studies, the combination of higher PEEP with LTV did not increase the occurrence of clinically objectified barotrauma. Therefore, a high PEEP may be safer for patients with ARDS when combined with LTV.

It is not clear from this study which method of setting PEEP was the best; there were many different methods of setting PEEP in each study, including oxygenation, stress index, transpulmonary pressure, decremental PEEP adjustment after a recruitment maneuver, or pressure-volume curves. These subgroup analyses could not be performed because of the small number of studies.

**Limitations**

The most important limitation was heterogeneity. There was variation in PEEP levels in the intervention group (PEEP at Day 1; 10-16.3 cmH₂O). In the control group, there was a similar variation in PEEP levels (PEEP at Day 1; 6.5-12.0 cmH₂O). The setting of the target PEEP level and the PEEP level of the control population may affect the effect of higher PEEP. Second, the P/F ratios of patients at inclusion also varied. Therefore, we performed a subgroup analysis using P/F ratios and found no interaction. Third, the definition of ARDS also varied among the studies, and subgroup analysis by ARDS definition did not show any interaction. Fourth, there may have been variabilities in important common interventions such as recruitment maneuvers and prone positions. The key common interventions were not specified by the studies; we could not verify whether there was an interaction between these subgroups. A meta-analysis by Walkey et al. reported that they did not detect any interaction by performing a protocolized recruitment maneuver [6].

**Conclusions**

Low-certainty evidence showed that the use of higher PEEP compared to the use of lower PEEP did not reduce mortality. However, the use of higher PEEP in patients with ARDS might be justified because it improves oxygenation without increasing harm and is associated with reduced mortality when combined with LTV. Further studies are needed to determine which subpopulations with higher PEEP are effective.

**Appendices**

**MEDLINE via PubMed search strategy (until July 8, 2020)**

#1 Respiratory Distress Syndrome, Adult[mh] OR ARDS[tiab] OR shock lung[tiab]

#2 acute respiratory distress[tiab] OR acute respiratory failure[tiab]

#3 Acute[tiab] AND ((respirat*[tiab] OR ventilat*[tiab] OR pulmon*[tiab]) AND (fail*[tiab] OR depression[tiab]))

#4 Lung injury[mh] OR ALI[tiab] OR Acute lung injur*[tiab] OR Ventilator-Induced Lung Injury[tiab]

#5 Respiratory insufficiency[mh] OR Respiratory insufficiency[tiab]

#6 Acute chest syndrome[mh] OR Acute chest syndrome[tiab]

#7 #1 OR #2 OR #3 OR #4 OR #5 OR #6
#8 Positive-Pressure Respiration[mh] OR Positive Pressure Respiration[ti,ab] OR Positive End-Expiratory Pressure[ti,ab] OR PEEP[ti,ab]

#9 Continuous Positive Airway Pressure[ti,ab] OR CPAP[ti,ab] OR NCPAP[ti,ab]

#10 Airway Pressure Release Ventilation[ti,ab] OR APRV[ti,ab]

#11 Intermittent Positive-Pressure Breathing[ti,ab] OR IPPB[ti,ab]

#12 Intermittent Positive-Pressure Ventilation[ti,ab] OR IPPV[ti,ab]

#13 lung protective ventilatory strategy[ti,ab] OR LPVS[ti,ab]

#14 alveolar recruitment[ti,ab] OR recruitment maneuver[ti,ab]

#15 #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14

#16 #7 AND #15

#17 (randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized[ti,ab] OR placebo[ti,ab] OR clinical trials as topic[mesh:noexp] OR randomly[ti,ab] OR trial[ti]) NOT (animals[mh] NOT humans [mh])

#18 #16 AND #17

**CENTRAL search strategy (until July 8, 2020)**

#1 [mh “Respiratory Distress Syndrome, Adult”] OR ARDS:ti,ab OR ‘shock lung’:ti,ab

#2 ‘acute respiratory distress’:ti,ab OR ‘acute respiratory failure’:ti,ab

#3 Acute:ti,ab AND ((respirat*:ti,ab OR ventilat*:ti,ab OR pulmon*:ti,ab) AND (fail*:ti,ab OR depression:ti,ab))

#4 [mh “lung injury”] OR ALI:ti,ab OR “Acute lung injury”:ti,ab OR “Ventilator-Induced Lung Injury”:ti,ab

#5 [mh “Respiratory insufficiency”] OR “Respiratory insufficiency”:ti,ab

#6 [mh “Acute chest syndrome”] OR “Acute chest syndrome”:ti,ab

#7 [OR #1–#6]

#8 [mh “Positive Pressure Respiration”] OR ‘Positive Pressure Respiration’:ti,ab OR ‘Positive End-Expiratory Pressure’:ti,ab OR PEEP:ti,ab

#9 ‘Continuous Positive Airway Pressure’:ti,ab OR CPAP:ti,ab OR NCPAP:ti,ab

#10 ‘Airway Pressure Release Ventilation’:ti,ab OR APRV:ti,ab

#11 ‘Intermittent Positive-Pressure Breathing’:ti,ab OR IPPB:ti,ab

#12 ‘Intermittent Positive-Pressure Ventilation’:ti,ab OR IPPV:ti,ab

#13 ‘lung protective ventilatory strategy’:ti,ab OR LPVS:ti,ab

#14 ‘Alveolar recruitment’:ti,ab OR ‘recruitment maneuvers’:ti,ab

#15 [OR #8–#14]

#16 #7 AND #15

#17 [mh animals] not [mh humans]

#18 #16 not #17
Embase search strategy (until June 28, 2020)
S1 (EMB.EXACT("adult respiratory distress syndrome")) OR (TL,AB(ARDS OR "shock lung"))
S2 (TL,AB("acute respiratory" p/0 (distress OR failure")))
S3 (TL,AB(acute n/3 (respirat* OR ventilat* OR pulmon*) n/3 (fail* OR depression)))
S4 (EMB.EXACT("acute lung injury")) OR (EMB.EXACT("hyperoxia-induced lung injury") OR EMB.EXACT("lung injury")) OR (EMB.EXACT("ventilator induced lung injury")) OR (TL,AB(ALI OR ("acute lung" p/0 injur*) OR "ventilator-Induced lung injury"))
S5 (EMB.EXACT.EXPLODE("respiratory failure")) OR (TL,AB(respiratory p/0 insufficien"))
S6 (EMB.EXACT("acute chest syndrome")) OR (TL,AB("acute chest syndrome"))
S7 (S1 OR S2 OR S3 OR S4 OR S5 OR S6)
S8 ((EMB.EXACT("positive end expiratory pressure")) OR (TL,AB(’positive pressure respiration’ OR ‘positive end-expiratory pressure’ OR PEEP))
S9 (TL,AB(“continuous positive airway pressure” OR CPAP OR NCPAP))
S10 (TL,AB("airway pressure release ventilation’ OR APRV))
S11 (TL,AB("intermittent positive-pressure breathing” OR IPPB))
S12 (TL,AB("intermittent positive-pressure ventilation’ OR IPPV))
S13 (TL,AB("lung protective’ p/0 ventilat* p/0 strateg*) OR LPVS))
S14 (TL,AB(“alveolar p/0 recruit*” OR (recruitment p/0 maneuver”)))
S15 (S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14)
S16 (S7 AND S15)
S17 (EMB.EXACT("controlled clinical trial") OR EMB.EXACT.EXPLODE("clinical trial (topic") OR EMB.EXACT("randomized controlled trial") OR (TL,AB(randomized) OR TL,AB(randomly) OR TI(trial))) NOT (ANIMAL(YES) NOT HUMAN(YES)))
S18 (S16 AND S17)

CINAHL search strategy (until July 12, 2020)
#1 (MH 'Respiratory Distress Syndrome, Adult') OR TI ARDS OR AB ARDS OR TI 'shock lung' OR AB 'shock lung'
#2 TI "acute respiratory distress" OR AB "acute respiratory distress" OR TI "acute respiratory failure" OR AB "acute respiratory failure"
#3 TI Acute OR AB Acute AND ((TI respirat* OR AB respirat* OR TI ventilat* OR AB ventilat* OR TI pulmon* OR AB pulmon*) AND (TI fail* OR AB fail* OR TI depression OR AB depression))
#4 (MH ‘Lung injury+’) OR TI ALI OR AB ALI OR TI ‘Acute lung injur’ OR AB ‘Acute lung injur’ OR TI ‘Ventilator-Induced Lung Injury’ OR AB ‘Ventilator-Induced Lung Injury’
#5 (MH ‘Respiratory Failure+’) OR TI ‘Respiratory Failure’ OR AB ‘Respiratory Failure’
#6 (MH ‘Acute chest syndrome’) OR TI ‘Acute chest syndrome’ OR AB ‘Acute chest syndrome’
#7 S1 OR S2 OR S3 OR S4 OR S5 OR S6
#8 (MH ‘Positive-Pressure Respiration+’) OR TI ‘Positive Pressure Respiration’ OR TI ‘Positive End-Expiratory Pressure’ OR AB ‘Positive End-Expiratory Pressure’ OR TI PEEP OR AB PEEP
Additional Information

Disclosures

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgements

We thank all members of the Japanese ARDS Clinical Practice Guideline Committee. We also appreciate Takaaki Suzuki, Nara Medical University Library and the librarian of Kyoto Prefectural University of Medicine Medical Library for developing the search strategy. We sincerely thank Dr. Takeaki Funamoto and Dr. Zhuan Jin for searching the Chinese articles and translating them.

References

1. Esteban A, Ferguson ND, Meade MO, et al.: Evolution of mechanical ventilation in response to clinical research. Am J Respir Crit Care Med. 2008, 177:170-7. 10.1164/rccm.200706-895OC
2. Villar J, Blanco J, Arión M, et al.: The ALIEN study: incidence and outcome of acute respiratory distress syndrome in the era of lung protective ventilation. Intensive Care Med. 2011, 37:1952-41. 10.1007/s00134-011-2380-4
3. Brower RG, Lanken PN, MacIntyre N, et al.: Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. N Engl J Med. 2004, 351:327-36. 10.1056/NEJMoa032193
4. Meade MO, Cook DJ, Guyatt GH, et al.: Ventilation strategy using low tidal volumes, recruitment maneuvers, and high positive end-expiratory pressure for acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA. 2008, 299:637-45. 10.1001/jama.299.6.637
5. Mercat A, Richard JC, Vielle B, et al.: Positive end-expiratory pressure setting in adults with acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA. 2008, 299:646-55. 10.1001/jama.299.6.646
6. Walkey AJ, Del Sorbo L, Hodgson CL, et al.: Higher PEEP versus lower PEEP strategies for patients with acute respiratory distress syndrome: a systematic review and meta-analysis. Ann Am Thorac Soc. 2017, 14:S297-30X. 10.1513/AnnalsATS.201704-339OT
7. Briel M, Meade M, Mercat A, et al.: Higher vs lower positive end-expiratory pressure in patients with acute

2022 Yamamoto et al. Cureus 14(7): e26957. DOI 10.7759/cureus.26957
lung injury and acute respiratory distress syndrome: systematic review and meta-analysis. JAMA. 2010, 303:865-75. 10.1001/jama.2010.218
8. Amato MB, Barbosa CS, Medeiros DM, et al.: Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. N Engl J Med. 1998, 338:547-54. 10.1056/NEJM199802053380602
9. Villar J, Kacmarek RM, Pérez-Méndez L, Aguirre-Jaimé A: A high positive end-expiratory pressure, low tidal volume ventilatory strategy improves outcome in persistent acute respiratory distress syndrome: a randomized, controlled trial. Crit Care Med. 2006, 34:1311-8. 10.1097/01.CCM.0000215598.84885.01
10. Santa Cruz R, Rojas I, Nervi R, Heredia R, Cliapponi A: High versus low positive end-expiratory pressure (PEEP) levels for mechanically ventilated adult patients with acute lung injury and acute respiratory distress syndrome. Cochrane Database Syst Rev. 2013, CD009908. 10.1002/14651858.CD009908.pub2
11. Guo L, Xie J, Huang Y, Pan C, Yang Y, Qiu H, Liu L: Higher PEEP improves outcomes in ARDS patients with clinically objective positive oxygenation response to PEEP: a systematic review and meta-analysis. BMC Anesthesiol. 2018, 18:172. 10.1186/s12871-018-0631-4
12. Hodgson CL, Cooper DJ, Arabi Y, et al.: Maximal recruitment open lung ventilation in acute respiratory distress syndrome (PHARLAP). A phase II, multicenter randomized controlled clinical trial. Am J Respir Crit Care Med. 2019, 200:1363-72. 10.1164/rccm.201901-0199OC
13. Lam NN, Hung TD, Hung DK: Impact of ‘opening the lung’ ventilatory strategy on burn patients with acute respiratory distress syndrome. Burns. 2019, 45:1841-7. 10.1016/j.burns.2019.05.016
14. Salem MS, Eltatawy HS, Abdelhafiz AA, Alsherif SE-DI: Lung ultrasound- versus FiO2-guided PEEP in ARDS patients. Egypt J Anaesth. 2020, 36:31-7. 10.1080/11101849.2020.1741255
15. Hashimoto S, Sanui M, Egi M, et al.: The clinical practice guideline for the management of ARDS in Japan . J Intensive Care. 2017, 5:50. 10.1186/s40560-017-0222-3
16. Murray JF, Matthay MA, Luce JM, Flick MR: An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis. 1988, 138:720-5. 10.1164/ajrccm/138.3.720
17. Bernard GR, Artigas A, Brigham KL, et al.: The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994, 149:818-24. 10.1164/ajrccm.149.3.7509706
18. Ranieri VM, Rubenfeld GD, Thompson BT, et al.: Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012, 307:2526-33. 10.1001/jama.2012.5669
19. Higgins JP, Altman DG, Gøtzsche PC, et al.: The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011, 343:d5928. 10.1136/bmj.d5928
20. Cochrane Handbook for Systematic Reviews of Interventions version 6.1 . (2020). http://www.training.cochrane.org/handbook.
21. Ranieri VM, Suter PM, Tortorella C, et al.: Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: a randomized controlled trial. JAMA. 1999, 282:52-61. 10.1001/jama.282.1.54
22. Long Y, Liu D-w, Zhou X, et al.: The application of individualized ventilation strategies in acute respiratory distress syndrome [Article in Chinese]. Zhonghua Jie He He Hu Xi Za Zhi. 2006, 29:549-53.
23. Talmor D, Sarge T, Malhotra A, et al.: Mechanical ventilation guided by esophageal pressure in acute lung injury. N Engl J Med. 2008, 359:2095-104. 10.1056/NEJMoa0708658
24. Hodgson CL, Tuxen DV, Davies AR, et al.: A randomised controlled trial of an open lung strategy with staircase recruitment, titrated PEEP and targeted low airway pressures in patients with acute respiratory distress syndrome. Crit Care. 2011, 15:R133. 10.1186/cc10249
25. Kacmarek RM, Villar J, Sulemanji D, et al.: Open lung approach for the acute respiratory distress syndrome: a pilot, randomized controlled trial. Crit Care Med. 2016, 44:52-42. 10.1097/CCM.0000000000001383
26. Cavalcanti AB, Suzumura ÉA, Laranjeira LN, et al.: Effect of lung recruitment and titrated positive end-expiratory pressure (PEEP) vs low PEEP on mortality in patients with acute respiratory distress syndrome: a randomized clinical trial. JAMA. 2017, 318:1535-45. 10.1001/jama.2017.14171
27. Li J, Luo Z, Li X, et al.: Effect of different transpulmonary pressures guided mechanical ventilation on respiratory and hemodynamics of patients with ARDS: a prospective randomized controlled trial [Article in Chinese]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2017, 29:39-44. 10.3760/cma.j.issn.2095-4552.2017.01.009
28. Wang B, Wu B, Ran YN: A clinical study on mechanical ventilation PEEP setting for traumatic ARDS patients guided by esophageal pressure. Technol Health Care. 2019, 27:57-47. 10.3253/THC-181580
29. Wang R, Sun B, Li X, et al.: Mechanical ventilation strategy guided by transpulmonary pressure in severe acute respiratory distress syndrome treated with veno-venous extracorporeal membrane oxygenation. Crit Care Med. 2020, 48:1280-8. 10.1097/CCM.0000000000004445